Clinical trials: Overactive Detrusor
Overactive Bladder
Use of Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) in Maintaining OAB Symptoms Improvement.
This study will help to determine the effectiveness of a self-supervised, home-based Transcutaneous Posterior Tibial Nerve Stimulation treatment protocol in maintaining Overactive Bladder (OAB) symptoms improvement in women…
- Trial name
- NCT02377765
- Testing
- Transcutaneous Stimulation, Percutaneus Stimulation
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Liverpool Women's NHS Foundation Trust
Spinal Cord Injuries (SCI), Detrusor Overactivity
The Effectiveness of Transcutaneous Sacral Neuromodulation Techniques-Magnetic Stimulation and Electrical Stimulation-on Detrusor Overactivity in Patients With Spinal Cord Injury
The goal of this prospective, randomized clinical trial is to compare the efficacy and safety of transcutaneous sacral magnetic stimulation versus sacral electrical stimulation for detrusor overactivity in 40 male and female…
- Trial name
- NCT07578532
- Testing
- Transcutaneous Sacral Electrical Stimulation, Transcutaneous sacral magnetic stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Ankara City Hospital Bilkent
Overactive Bladder, Overactive Bladder Syndrome
Developing a Simple Test to Diagnose Overactive Bladder
In order to develop a test to diagnose overactive bladder from urine, it is essential that this test is at least as accurate as the tools that clinicians currently use.
- Conditions
- Overactive Bladder, Overactive Bladder Syndrome, Detrusor Overactivity
- Trial name
- NCT05572918
- Testing
- Urodynamics aka filling cystometry
- Volunteers
- 100 people
- Sponsor
- Teesside University
Urinary Bladder Neurogenic Dysfunction
Neuro-urological Outcome After Spinal Cord Injury
Most patients with spinal cord injury suffer from bladder dysfunction which may - especially in the long-term - impair renal function. Improved treatment during the last decades improved life expectancy and quality of life.
- Trial name
- NCT01297660
- Testing
- Video-urodynamic examination
- Where
- Switzerland
- Volunteers
- 55 people
- Sponsor
- Balgrist University Hospital
Neurogenic Detrusor Overactivity
Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity
The objective of the study was to evaluate the efficacy, safety, tolerability and pharmacokinetics of mirabegron after multiple-dose administration in the pediatric population.
- Trial name
- Crocodile (NCT02751931)
- Testing
- Mirabegron
- Where
- 32 sites in Australia, Belgium and 17 more
- Volunteers
- 91 people
- Sponsor
- Astellas Pharma Europe B.V.
Spinal Cord Injuries, Neurogenic Detrusor Overactivity
TTNS in SCI Patients With Neurogenic Detrusor Overactivity
This is a prospective, single-arm, pilot study to assess effectiveness and tolerability of transcutaneous tibial nerve stimulation (TTNS) in managing neurogenic detrusor overactivity in spinal cord injury patients.
- Trial name
- NCT07785258
- Testing
- TTNS
- Where
- Singapore
- Volunteers
- 12 people
- Sponsor
- National University Hospital, Singapore
Bladder Dysfunction, Overactive Bladder
Noninvasive Ultrasound Assessment of Detrusor Dysfunction
The purpose of this study is to test a new ultrasound method called Quantitative Ultrasound Bladder Vibrometry to detect abnormal bladder function.
- Conditions
- Bladder Dysfunction, Overactive Bladder, BPH With Urinary Obstruction
- Trial name
- NUADD (NCT05652023)
- Where
- United States
- Volunteers
- 2,023 people
- Sponsor
- Mayo Clinic
Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for…
- Trial name
- CONTENT2 (NCT02660359)
- Testing
- Botulinum toxin type A
- Where
- 82 sites in Argentina, Australia and 14 more
- Volunteers
- 258 people
- Sponsor
- Ipsen
Overactive Bladder
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
The main hypothesis of this study is that magnetic neuromodulation can be used to correct bladder overactivity. The investigators assume that the transvertebral magnetic stimulation can improve both the subjective state of…
- Trial name
- NCT04578899
- Testing
- Transvertebral magnetic stimulation
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Joint-Stock Company North-West Center for Evidence-Based Medicine, Russian Federation
Detrusor Overactivity, Overactive Bladder
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.
- Trial name
- SHRINK (NCT01093534)
- Testing
- solifenacin
- Where
- 79 sites in United States, Austria and 18 more
- Volunteers
- 547 people
- Sponsor
- Astellas Pharma Inc
Urinary Bladder, Overactive, Urodynamics
Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity
To investigates the effects of botulinum toxin type A bladder injection compared to combined pharmacotherapy with Mirabegron and Solifenacin.
- Conditions
- Urinary Bladder, Overactive, Urodynamics, Effect of Drug
- Trial name
- NCT05968885
- Testing
- Intradetrusor Botox® (onabotulinumtoxinA) injection, Combine Mirabegron and Solifenacin.
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Mackay Memorial Hospital
Spinal Cord Injuries (SCI)
The Predictive Value of Lower Extremity Hypertonia on Neurogenic Detrusor Overactivity After Spinal Cord Injury
The goal of this observational study is to evaluate whether increased lower extremity muscle tone can serve as an independent predictor of neurogenic detrusor overactivity (NDO) in adult patients (aged 18-80 years) with upper…
- Trial name
- NCT07695662
- Volunteers
- 300 people
- Sponsor
- Shengjing Hospital
Detrusor Overactivity
Ultrasonographic Bladder Wall Thickness and Different Forms of Detrusor Overactivity
In the last decade, several authors proposed ultrasound measurement of Bladder wall thickness (BWT) for the screening of the voiding dysfunction and of the detrusor overactivity (DO).
- Trial name
- NCT01003457
- Testing
- ultrasonography
- Where
- Italy
- Volunteers
- healthy volunteers welcome
- Sponsor
- Università degli Studi dell'Insubria
Detrusor Function, Overactive
Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity
The purpose of this study is to evaluate the effects and tolerability (how well a participant can stand a particular medicine or treatment) of flexible dose Oxybutynin Extended-Release (OXY-ER, Lyrinel) including safety and…
- Trial name
- RONDO (NCT01796548)
- Testing
- Oxybutinin Extended-Release
- Where
- 3 sites in Thailand
- Volunteers
- 17 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Neurogenic Detrusor Overactivity
A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity
People with neurogenic detrusor overactivity (NDO) have poor bladder control because of how their nerves to the bladder are wired. This can cause high pressure in the bladder, causing it to leak urine by accident (incontinence).
- Trial name
- NCT05621616
- Testing
- mirabegron
- Where
- 3 sites in Philippines, Poland
- Volunteers
- 7 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Overactive Bladder, Neurogenic Detrusor Overactivity
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
The purpose of the study is to evaluate the pharmacokinetics (PK) of mirabegron oral suspension after single dose administration in children with neurogenic detrusor overactivity (NDO) or overactive bladder (OAB).
- Trial name
- NCT02526979
- Testing
- mirabegron
- Where
- 3 sites in Denmark, Poland
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Europe B.V.
Parkinson's Disease, Multiple System Atrophy
Botulinum A Toxin in Patients With Parkinson's Disease
The researchers investigated the effectiveness and safety of BoNT/A injected into the detrusor muscle in patients with PD and MSA all of whom had detrusor muscle overactivity unresponsive to conventional medical therapy.
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Detrusor Overactivity
- Trial name
- Botox-PD (NCT00822913)
- Testing
- Intravesical injection of Botulinum A toxin
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Of Perugia
Overactive Bladder
Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy
This study evaluated the outcomes of women with detrusor overactivity treated with combined pharmacotherapy to identify risk factors for treatment failure.
- Trial name
- NCT07337252
- Testing
- Combined pharmacotherapy
- Where
- Taiwan
- Volunteers
- 61 people
- Sponsor
- Mackay Memorial Hospital
Overactive Detrusor, Detrusor Hyperreflexia of Bladder
Onabotulinumtoxina Intradetrusorial Injections and NGF Expression
In the last years, botulinum toxin type A (onab/A) has been increasingly used as a treatment option for overactive bladder symptoms in patients affected by either neurogenic and idiopathic detrusor overactivity (DO).
- Trial name
- Onab/A-NGF (NCT01629433)
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- University Of Perugia
Overactive Bladder Syndrome, Detrusor Overactivity
Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker
About one to two million women in Taiwan suffers from overactive bladder (OAB). The most commonly used anti-muscarinic drugs have a high rate of side effects.
- Trial name
- NCT04693897
- Testing
- Mirabegron 50 MG, Solifenacin Succinate 5 MG
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital